Annual Report for 2013 on Form 20-F filed with the SEC on April 4, 2014

Annual Report for 2013 on Form 20-F filed with the SEC on April 4, 2014 
BARCELONA, Spain, April 4, 2014 /CNW/ - Grifols, S.A. ("Grifols") (MCE:GRF, 
MCE:GRF.P and NASDAQ:GRFS), announced that it has filed its 2013 Annual Report 
on Form 20-F with the United States Securities and Exchange Commission ("SEC") 
on April 4, 2014. Grifols' Annual Report on Form 20-F includes its audited 
financial statements for its fiscal year ended December 31, 2013. 
Form 20-F can be accessed electronically through the Grifols website at 
http://inversores.grifols.com/portal/es/grifols/sec_filings. The Form 20-F is 
also available on the SEC's website at http://www.sec.gov . 
Grifols will deliver, within a reasonable time after request, a hard copy of 
the Form 20-F, including its complete audited financial statements, free of 
charge, to any shareholder upon request. To request a hard copy, shareholders 
may contact Grifols by email at investors@grifols.com to the attention of 
Grifols's Investor Relations, Re: 2013 Annual Report on Form 20-F. 
About Grifols Grifols is a global healthcare company with a 70-year legacy of 
improving people's health and well being through the development of 
life-saving plasma medicines, diagnostics systems, and hospital pharmacy 
products. 
The company is present in more than 100 countries worldwide and is 
headquartered in Barcelona, Spain. Grifols is a leader in plasma collection 
with a network of 150 plasma donor centers in the U.S., and a leading producer 
of plasma-derived biological medicines. The company also provides a 
comprehensive range of transfusion medicine, hemostasis, and immunoassay 
solutions for clinical laboratories, blood banks and transfusion centers, and 
is a recognized leader in transfusion medicine. 
In 2013, sales exceeded 2,740 million euros with a headcount of 13,200 
employees. Grifols demonstrates its commitment to advancing healthcare by 
allocating a significant portion of its annual income to R&D. 
The company's class A shares are listed on the Spanish Stock Exchange, where 
they are part of the Ibex-35 (MCE:GRF).  Its non-voting class B shares are 
listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs 
(NASDAQ: GRFS). For more information visit www.grifols.com.
 

SOURCE  Grifols, S.A. 
Punkaj Amin, 1-919-316-6664 
http://www.grifols.com 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/April2014/04/c8664.html 
CO: Grifols, S.A.
NI: HEA BTC MTC  
Press spacebar to pause and continue. Press esc to stop.